<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:hpo ids='HP_0002020'>Gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) is a pathology with a wide range of clinical and endoscopic manifestations </plain></SENT>
<SENT sid="1" pm="."><plain>Epidermal growth factor receptor (EGFR), found in the epithelium of the digestive tract, plays an important role in epithelial repair and shows increased expression in different <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, including <z:e sem="disease" ids="C0014859" disease_type="Neoplastic Process" abbrv="">esophageal tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVES: The purpose of this study was to evaluate EGFR expression using immunohistochemistry in esophageal biopsies obtained from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> of the esophagus </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: EGFR expression was immunohistochemically determined in biopsies from 194 patients with symptoms suggestive of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> or <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> of the esophagus, seen at two Brazilian university hospitals between January 2003 and December 2008 </plain></SENT>
<SENT sid="4" pm="."><plain>Based on histopathological analysis, patients were divided into three groups: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> of the esophagus </plain></SENT>
<SENT sid="5" pm="."><plain>EGFR expression was considered positive when staining was detected in the membrane </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Mean age was 55.25 years (range 30-90) </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> (n = 127) accounted for 65.5% of the sample, compared with 12.4% (n = 24) of patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and 22.2% (n = 43) of patients with esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Immunohistochemical analysis was positive for EGFR in 19.1% of the patients (37/194), divided as follows: 8.7% (11/127) in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> group, 25% (6/24) in the <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> group, and 46.5% (20/43) in the esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> group </plain></SENT>
<SENT sid="9" pm="."><plain>Statistical analysis revealed significant differences between the three groups (p = 0.0001) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> patients showed lower levels of EGFR expression than patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> or patients with <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> of the esophagus, suggesting a direct relationship between EGFR expression and disease progression </plain></SENT>
</text></document>